Capital Analysts LLC’s IGC Pharma IGC Stock Holding History

Capital Analysts LLC’s Portfolio IGC Stock Details IGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-307	Closed	-$1K	–	1007
2021 Q1	$1K	Buy	+307	New	+$558	﹤0.01%	1017

Other funds holding IGC

IEFM

IQ EQ Fund Management Dublin 2, Ireland $1.32B AUM 31.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Dearborn Partners Chicago, Illinois $1.85B AUM 6.59% 1-Year Est. Return

Capital Analysts LLC's IGC Position: Q2 2021 in Review

Capital Analysts LLC sold out of IGC Pharma (IGC) in Q2 2021, closing a stake of 307 shares — an estimated $1K sold.

Capital Analysts LLC first reported a position in IGC in Q1 2021 and held it in 1 quarter. The position peaked at $1K in Q1 2021. 29 funds tracked by Wall St. Rank hold IGC as of Q2 2021.

Capital Analysts LLC reported no remaining IGC Pharma position as of Q2 2021 after selling out during the quarter.
Capital Analysts LLC sold 307 IGC Pharma shares in Q2 2021, an estimated $1K.
Capital Analysts LLC first reported a position in IGC Pharma in Q1 2021 and held it in 1 quarter.
Capital Analysts LLC's IGC Pharma position peaked at $1K in Q1 2021.
29 funds tracked by Wall St. Rank held IGC Pharma as of Q2 2021.

Based on Capital Analysts LLC's 13F filing for Q2 2021, filed 5 Aug 2021.